GlaxoSmithKline News

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Nov 22 22:25

6-K: Transaction Notification

Nov 19 23:56

6-K: Linerixibat Shows Positive Phase Iii Results in Cholestatic Pruritus in Primary Biliary Cholangitis

Nov 19 21:11

6-K: Lenrep Shows Overall Survival Benefit in Head-to-Head Dreamm-7 Phase Iii Trial for Relapsed/Refractory Multiple Myeloma

Nov 14 19:46

6-K: Block Listing Six Monthly Return

Nov 13 23:17

6-K: Transaction Notification

Nov 12 23:33

6-K: Gsk Publishes Provisional Dividend Dates

Nov 12 22:48

6-K: Total voting rights and capital

Nov 1 23:22

6-K: Transaction notification

Oct 31 00:32

6-K: New data for arexvy, gsk's respiratory syncytial virus vaccine, show potential to help protect a broader group of adults at increased risk for rsv disease

Oct 24 18:53

6-K: Transaction Notification

Oct 18 00:07

6-K: Transaction Notification

Oct 17 00:57

6-K: Gepotidacin Accepted for Priority Review by Us Fda for Treatment of Uncomplicated Urinary Tract Infections in Female Adults and Adolescents

Oct 16 18:27

6-K: Transaction Notification

Oct 15 18:40

6-K: Gsk Announces Positive Phase Iii Results from Anchor Trials for Depemokimab in Chronic Rhinosinusitis with Nasal Polyps

Oct 15 18:18

6-K: Transaction Notification

Oct 11 23:58

6-K: Transaction Notification

Oct 10 23:04

6-K: Statement: Zantac (Ranitidine) Litigation - Settlement Agreements Reached

Oct 10 01:32

6-K: Gsk Presents Positive Data for Arexvy, Its Respiratory Syncytial Virus (Rsv) Vaccine, Indicating Protection over Three Rsv Seasons

Oct 8 21:26

6-K: Total Voting Rights and Capital

Oct 1 23:15